Marché de la biopsie liquide en Asie-Pacifique – Tendances et prévisions de l’industrie jusqu’en 2030

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché de la biopsie liquide en Asie-Pacifique – Tendances et prévisions de l’industrie jusqu’en 2030

  • Healthcare
  • Publish Reports
  • May 2023
  • Asia-Pacific
  • 350 Pages
  • Nombre de tableaux : 372
  • Nombre de figures : 56

Asia Pacific Liquid Biopsy Market

Taille du marché en milliards USD

TCAC :  % Diagram

Diagram Période de prévision
2024 –2030
Diagram Taille du marché (année de référence)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram Taille du marché (année de prévision)
MILLIONS DE DOLLARS AMÉRICAINS
Diagram TCAC
%
DiagramPrincipaux acteurs du marché
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5 < /li>

>Marché de la biopsie liquide en Asie-Pacifique, par produit (instruments, consommables et accessoires, services et logiciels), type de biofabricant ( cellules tumorales circulantes (CTCS) , ADN acellulaire circulant (CFDNA), ARN acellulaire, vésicules extracellulaires, exosomes et autres), type d'échantillon (basé sur un échantillon de sang, basé sur un échantillon d'urine, basé sur un échantillon de salive et d'autres liquides tissulaires, et autres), type d'analyse (moléculaire, protéomique et histologie/imagerie), type d'application (applications cancéreuses et applications non cancéreuses), application clinique (dépistage de routine, bilan des patients, sélection de thérapie, surveillance du traitement, surveillance des récidives et autres), technologie (analyse parallèle multigénique et analyse monogénique), utilisateur final (hôpitaux, laboratoires de référence, centres de diagnostic, centres de recherche et instituts universitaires, et autres), canal de distribution (appel d'offres direct, distributeur tiers et autres) - Tendances de l'industrie et prévisions jusqu'en 2030.

Marché de la biopsie liquide en Asie-Pacifique

Analyse et perspectives du marché de la biopsie liquide en Asie-Pacifique

La prise de conscience croissante des technologies de diagnostic avancées en Asie-Pacifique a accru la demande sur le marché. L'augmentation des dépenses de santé pour de meilleurs services de santé contribue également à la croissance du marché. Les principaux acteurs du marché se concentrent sur le lancement et l'approbation de divers services au cours de cette période cruciale. En outre, l'amélioration des processus et des techniques contribue également à la demande croissante de biopsie liquide.

Marché de la biopsie liquide en Asie-PacifiqueMarché de la biopsie liquide en Asie-Pacifique

Le marché de la biopsie liquide en Asie-Pacifique devrait croître au cours de l'année de prévision en raison de l'augmentation du nombre d'acteurs sur le marché et de la disponibilité de services avancés. Parallèlement à cela, les fabricants sont engagés dans l'activité de développement pour lancer de nouveaux services sur le marché. Le développement croissant dans le domaine des techniques de soins de santé avancées stimule encore davantage la croissance du marché.

Cependant, des difficultés telles que le manque de protocoles standardisés et le manque de professionnels qualifiés pourraient entraver la croissance du marché de la biopsie liquide en Asie-Pacifique au cours de la période de prévision.

Data Bridge Market Research analyse que le marché de la biopsie liquide en Asie-Pacifique devrait croître à un TCAC de 13,4 % au cours de la période de prévision de 2023 à 2030.

Rapport métrique

Détails

Période de prévision

2023 à 2030

Année de base

2022

Années historiques

2021 (personnalisable de 2015 à 2020)

Unités quantitatives

Chiffre d'affaires en millions, volumes en unités, prix en USD

Segments couverts

Product (Instruments, Consumables & Accessories, Services & Software), Biomaker Type (Circulating Tumor Cells (CTCS), Circulating Cell-Free DNA (CFDNA), Cell-free RNA, Extracellular Vesicles, Exosomes, and Others), Sample Type (Blood Sample-Based, Urine Sample-Based, Saliva & Other Tissue Fluid Sample-Based, and Others), Analytical Type (Molecular, Proteomics, and Histology/Imaging), Application Type (Cancer Applications and Non-Cancer Applications), Clinical Application (Routine Screening, Patient Work-Up, Therapy Selection, Treatment Monitoring, Recurrence Monitoring, and Others), Technology (Multi-Gene Parallel Analysis, and Single-Gene Analysis), End User (Hospitals, Reference Laboratories, Diagnostic Centers, Research Centers & Academic Institutes, and Others), Distribution Channel (Direct Tender, Third Party Distributor, and Others)

Countries Covered

Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of Asia-Pacific

Market Players Covered

F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc., and BIOCEPT, INC. among others

Market Definition

A liquid biopsy is a medical test that involves the analysis of various biomolecules, such as DNA, RNA, proteins, and other substances in a patient's blood or other bodily fluids, to diagnose and monitor various medical conditions, including cancer. Unlike traditional biopsies that involve the removal of tissue samples from the body, a liquid biopsy is non-invasive and can provide important diagnostic information without the need for surgery or other invasive procedures. Liquid biopsies are still in the early stages of development but hold promise for improving the detection and management of cancer and other diseases.

Asia-Pacific Liquid Biopsy Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below

Drivers

  • Growing demand for non-invasive liquid biopsy technique

Liquid biopsies consist of isolating tumor-derived entities such as circulating tumor cells, circulating tumor DNA, and tumor extracellular vesicles among others, present in the body fluids of patients with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation and analysis of liquid biopsies have rapidly evolved over the past few years, as described in the review, thus providing greater details about tumor characteristics such as mutations, tumor staging, tumor progression, heterogeneity, and gene and clonal evolution, among others. Liquid biopsies from cancer patients have opened up newer avenues in detection and continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance. Non-invasive cancer diagnostics offer a safer and more patient-friendly approach, resulting in a growing demand for these methods.

  • Advancements in precision medicine due to liquid biopsy

Precision medical oncology in the clinical management of cancer may be achieved through the diagnostic platform called "liquid biopsy" (LB). The LB was recognized as a powerful real-time approach for the molecular monitoring of this dynamic cancer disease. This method utilizes the detection of Biomarkers in blood for prognostic and predictive purposes by non-invasive means, which in the near future will represent a change in the paradigm of molecular biology understanding and the heterogeneity of tumors. Advancements in precision medicine, fueled by the use of liquid biopsy techniques, have contributed significantly to the growing demand for non-invasive cancer diagnostics. Liquid biopsy techniques, such as the analysis of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes in blood or other body fluids, provide valuable information about the genetic makeup of tumors, enabling precision medicine approaches in cancer care.

Opportunity

  • Integration of Artificial Intelligence (AI) and machine learning

Liquid biopsy-based approaches offer many new opportunities to measure molecular Biomakers for diagnosing, prognosis, and monitoring disease. Artificial Intelligence (AI), such as machine learning, and its ability to identify signatures of specific disease states in multiplexed data will be key to taking advantage of the new molecular information that microchip-based diagnostics can extract.

Thus, the integration of AI and machine learning is expected to act as an opportunity for the growth of the market.

  • Increasing reimbursements and government support for liquid biopsy

The adoption of liquid biopsy has been significantly influenced by government backing. Governments throughout the world have put legislation in place to encourage the adoption of liquid biopsy because they understand how it may enhance patient care, lower healthcare costs, and advance precision medicine. Incorporating liquid biopsy into national cancer screening programs or treatment recommendations is only one example of how this might be done. Other examples include financing for research and development of liquid biopsy technologies and backing clinical trials and studies to produce evidence on their therapeutic efficacy. Such government assistance has aided in boosting liquid biopsy test knowledge, adoption, and reimbursement coverage.

Thus, increasing reimbursements and government support for liquid biopsy is expected to act as an opportunity for the market's growth.

Restraint/Challenge

  • High cost of liquid biopsy tests

The liquid biopsy is severely constrained by the high cost. While liquid biopsy tests show promise for non-invasive illness detection and monitoring, including cancer, there are cost-related obstacles that may prevent their widespread use.

The necessity for specialized tools and technologies is one of the biggest economic obstacles. Costly tools, including digital PCR machines, NGS platforms, and automated sample processing systems, are frequently needed for liquid biopsy studies. Smaller healthcare facilities with tighter budgets may find it difficult to afford the initial investment and ongoing maintenance costs connected with these technologies, which limits their capacity to provide liquid biopsy tests to patients.

Thus, the high cost of liquid biopsy tests is expected to restrain the market's growth.

  • Lack of skilled professionals performing liquid biopsy

The demand for liquid biopsy tests is increasing due to their potential clinical utility in cancer detection, monitoring, and personalized treatment decision-making. However, there may be limited resources, including personnel, equipment, and funding, to support the implementation of liquid biopsy programs in healthcare institutions. This can result in a shortage of skilled professionals who can perform liquid biopsy tests, especially in regions or healthcare settings with limited resources.

Thus, the lack of skilled professionals performing liquid biopsies is expected to challenge the market growth.

Recent Development

  • In January 2022, Exact Sciences Corporation announced the acquisition of Prevention Genetics, a genetic testing laboratory, to complement its advanced cancer diagnostics portfolio and support its entrance into hereditary cancer testing (HCT).

Asia-Pacific Liquid Biopsy Market Scope

The Asia-Pacific liquid biopsy market is categorized into nine notable segments which are product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel. The growth amongst these segments will help you analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

  • Instruments
  • Consumables & Accessories
  • Services & Software

On the basis of product, the market is segmented into instruments, consumables & accessories, services & software.

Biomaker Type

  • Circulating Tumor Cells (CTCS)
  • Circulating Cell-Free DNA (CFDNA)
  • Cell-Free RNA
  • Exosomes
  • Extracellular vesicles
  • Others

On the basis of biomaker type, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), cell-free RNA, extracellular vesicles, exosomes, and others.

Sample Type

  • Blood Sample-Based
  • Urine Sample-Based
  • Saliva & Other Tissue Fluids Sample-Based
  • Others

On the basis of sample type, the market is segmented into blood sample-based, urine sample-based, saliva & other tissue fluid sample-based, and others.

Analytical Type

  • Molecular
  • Proteomic
  • Histology/Imaging

On the basis of analytical type, the market is segmented into molecular, proteomics, and histology/imaging.

Application Type

  • Cancer Applications
  • Non-Cancer Applications

On the basis of application type, the market is segmented into cancer applications and non-cancer applications.

Clinical Application

  • Routine Screening
  • Therapy Selection
  • Treatment Monitoring
  • Recurrence Monitoring
  • Patient Work-Up
  • Others

On the basis of clinical application, the market is segmented into routine screening, patient work-up, therapy selection, treatment monitoring, recurrence monitoring, and others.

Technology

  • Multi-Gene-Parallel Analysis
  • Single Gene Analysis

On the basis of technology, the market is segmented into multi-gene parallel analysis and single-gene analysis.

End User

  • Hospitals
  • Reference Laboratories
  • Diagnostics Centers
  • Research Centres and Academic Institutes
  • Others

On the basis of end user, the market is segmented into hospitals, reference laboratories, diagnostic centers, research centers & academic institutes, and others.

Distribution Channels

  • Direct Tender
  • Third Party Distributor
  • Others

On the basis of distribution channel, the market is segmented into direct tender, third party distributor, and others.

Marché de la biopsie liquide

Asia-Pacific Liquid Biopsy Market Regional Analysis/Insights

The Asia-Pacific liquid biopsy market is analyzed, and market size insights and trends are provided based on product, biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel.

The countries covered in this market report are Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, and Rest of Asia-Pacific.

En 2023, le Japon devrait dominer le marché de la biopsie liquide en Asie-Pacifique en raison des avancées technologiques des plateformes de biopsie liquide du pays.

La section par pays du rapport fournit également des facteurs individuels ayant un impact sur le marché et des changements dans la réglementation du marché qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques, l'analyse des cinq forces de Porter et les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques d'Asie-Pacifique et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales et de l'impact des tarifs nationaux et des routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données par pays.

Analyse du paysage concurrentiel et des parts de marché de la biopsie liquide en Asie-Pacifique

Le paysage concurrentiel du marché de la biopsie liquide en Asie-Pacifique fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie-Pacifique, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement de produits, les pipelines d'essais cliniques, l'analyse de la marque, les approbations de produits, les brevets, la largeur et l'étendue du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché de la biopsie liquide en Asie-Pacifique.

Certains des principaux acteurs du marché de la biopsie liquide en Asie-Pacifique sont F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc. et BIOCEPT, INC. entre autres.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT TYPE LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET TESTING TYPE COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 INDUSTRY INSIGHTS:

6 ASIA-PACIFIC LIQUID BIOPSY MARKET, REGULATION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 GROWING DEMAND FOR NON-INVASIVE LIQUID BIOPSY TECHNIQUE

7.1.2 ADVANCEMENTS IN PRECISION MEDICINE DUE TO LIQUID BIOPSY

7.1.3 INCREASING CANCER PREVALENCE AND AWARENESS

7.1.4 TECHNOLOGICAL ADVANCEMENTS IN LIQUID BIOPSY PLATFORMS

7.2 RESTRAINTS

7.2.1 HIGH COST OF LIQUID BIOPSY TESTS

7.2.2 LACK OF STANDARDIZED GUIDELINES

7.3 OPPORTUNITIES

7.3.1 INTEGRATION OF ARTIFICIAL INTELLIGENCE (AI) AND MACHINE LEARNING

7.3.2 INCREASING REIMBURSEMENTS AND GOVERNMENT SUPPORT FOR LIQUID BIOPSY

7.3.3 INCREASING R&D ACTIVITIES BY INSTITUTES

7.4 CHALLENGES

7.4.1 LACK OF SKILLED PROFESSIONALS PERFORMING LIQUID BIOPSY

7.4.2 INCREASED DEPENDENCY ON OTHER BIOPSIES

8 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & ACCESSORIES

8.2.1 TEST KITS

8.2.1.1 TOTAL NUCLEIC ACID ISOLATION KIT

8.2.1.2 DNA ISOLATION KIT

8.2.1.3 OTHERS

8.2.2 COLLECTION TUBES

8.2.2.1 50 PIECES

8.2.2.2 100 PIECES

8.2.3 ASSAYS

8.2.3.1 FLEXIBLE REAGENTS

8.2.3.2 SCALABLE REAGENTS

8.2.3.3 OTHERS

8.2.4 CONTROL KIT

8.2.5 OTHERS

8.3 INSTRUMENTS

8.3.1 ANALYZERS

8.3.2 SYSTEMS

8.3.3 OTHERS

8.4 SERVICES & SOFTWARE

8.4.1 NGS ANALYSIS AND REPORTING SOFTWARE

8.4.2 DPCR ANALYSIS SOFTWARE

8.4.3 CASTPCR ANALYSIS SOFTWARE

8.4.4 OTHERS

9 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE

9.1 OVERVIEW

9.2 CIRCULATING TUMOR CELLS (CTCS)

9.3 CIRCULATING CELL-FREE DNA (CFDNA)

9.4 CELL-FREE RNA

9.5 EXOSOMES

9.6 EXTRACELLULAR VESICLES

9.7 OTHERS

10 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE

10.1 OVERVIEW

10.2 BLOOD SAMPLE-BASED

10.3 URINE SAMPLE-BASED

10.4 SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED

10.5 OTHERS

11 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE

11.1 OVERVIEW

11.2 MOLECULAR

11.2.1 NGS

11.2.2 PCR

11.2.3 MICROARRAY

11.2.4 PROTEOMICS

11.2.5 OTHERS

11.3 PROTEOMIC

11.3.1 NGS

11.3.2 PCR

11.3.3 MICROARRAY

11.3.4 PROTEOMICS

11.3.5 OTHERS

11.4 HISTOLOGY/IMAGING

12 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE

12.1 OVERVIEW

12.2 CANCER APPLICATIONS

12.2.1 LUNG

12.2.2 BREAST

12.2.2.1 EARLY BREAST CANCER

12.2.2.2 ADVANCED BREAST CANCER

12.2.3 COLORECTAL

12.2.4 PROSTRATE

12.2.5 LIVER

12.2.6 OTHERS

12.3 NON-CANCER APPLICATIONS

12.3.1 PRENATAL DIAGNOSIS

12.3.2 PERSONALIZED IMMUNOTHERAPY

12.3.3 OTHERS

13 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION

13.1 OVERVIEW

13.2 ROUTINE SCREENING

13.3 THERAPY SELECTION

13.4 TREATMENT MONITORING

13.4.1 EARLY-STAGE DISEASE

13.4.2 LATE-STAGE/METASTATIC DISEASE

13.5 RECURRENCE MONITORING

13.6 PATIENT WORK-UP

13.7 OTHERS

14 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY

14.1 OVERVIEW

14.2 MULTI-GENE-PARALLEL ANALYSIS

14.3 SINGLE GENE ANALYSIS

15 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 REFERENCE LABORATORIES

15.4 DIAGNOSTIC CENTERS

15.5 RESEARCH CENTERS AND ACADEMIC INSTITUTES

15.6 OTHERS

16 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 DIRECT TENDER

16.3 THIRD PARTY DISTRIBUTOR

16.4 OTHERS

17 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY REGION

17.1 ASIA-PACIFIC

17.1.1 JAPAN

17.1.2 CHINA

17.1.3 SOUTH KOREA

17.1.4 INDIA

17.1.5 AUSTRALIA

17.1.6 SINGAPORE

17.1.7 THAILAND

17.1.8 MALAYSIA

17.1.9 INDONESIA

17.1.10 PHILIPPINES

17.1.11 REST OF ASIA-PACIFIC

18 ASIA-PACIFIC LIQUID BIOPSY MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19 COMPANY PROFILE

19.1 F. HOFFMANN-LA ROCHE LTD.

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 GUARDANT HEALTH

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 THERMO FISHER SCIENTIFIC INC.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 SWOT ANALYSIS

19.3.5 PRODUCT PORTFOLIO

19.3.6 RECENT DEVELOPMENTS

19.4 EXACT SCIENCE CORPORATION

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENTS

19.5 QIAGEN

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENTS

19.6 ANGLE PLC (2022)

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.6.4 RECENT DEVELOPMENT

19.7 BIOCEPT, INC.

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.7.4 RECENT DEVELOPMENT

19.8 BIO-RAD LABORATORIES, INC. (2022)

19.8.1 COMPANY SNAPSHOT

19.8.2 REVENUE ANALYSIS

19.8.3 PRODUCT PORTFOLIO

19.8.4 RECENT DEVELOPMENTS

19.9 EPIC SCIENCES

19.9.1 COMPANY SNAPSHOT

19.9.2 PRODUCT PORTFOLIO

19.9.3 RECENT DEVELOPMENTS

19.1 FLUXION BIOSCIENCES INC

19.10.1 COMPANY SNAPSHOT

19.10.2 PRODUCT PORTFOLIO

19.10.3 RECENT DEVELOPMENTS

19.11 ILLUMINA, INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 SWOT ANALYSIS

19.11.4 PRODUCT PORTFOLIO

19.11.5 RECENT DEVELOPMENT

19.12 JOHNSON & JOHNSON PRIVATE LIMITED

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 SWOT ANALYSIS

19.12.4 PRODUCT PORTFOLIO

19.12.5 RECENT DEVELOPMENTS

19.13 LABORATORY CORPORATION OF AMERICA HOLDINGS

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 SWOT ANALYSIS

19.13.4 PRODUCT PORTFOLIO

19.13.5 RECENT DEVELOPMENT

19.14 MDXHEALTH

19.14.1 COMPANY SNAPSHOT

19.14.2 REVENUE ANALYSIS

19.14.3 PRODUCT PORTFOLIO

19.14.4 RECENT DEVELOPMENTS

19.15 MENARINI SILICON BIOSYSTEMS

19.15.1 COMPANY SNAPSHOT

19.15.2 PRODUCT PORTFOLIO

19.15.3 RECENT DEVELOPMENTS

19.16 NATERA, INC.

19.16.1 COMPANY SNAPSHOT

19.16.2 REVENUE ANALYSIS

19.16.3 PRODUCT PORTFOLIO

19.16.4 RECENT DEVELOPMENTS

19.17 NEOGENOMICS LABORATORIES

19.17.1 COMPANY SNAPSHOT

19.17.2 REVENUE ANALYSIS

19.17.3 PRODUCT PORTFOLIO

19.17.4 RECENT DEVELOPMENTS

19.18 ONCOCYTE CORPORATION

19.18.1 COMPANY PROFILE

19.18.2 SERVICE PORTFOLIO

19.18.3 RECENT DEVELOPMENTS

19.19 PATHAI

19.19.1 COMPANY SNAPSHOT

19.19.2 PRODUCT PORTFOLIO

19.19.3 RECENT DEVELOPMENTS

19.2 PREDICINE

19.20.1 COMPANY SNAPSHOT

19.20.2 PRODUCT PORTFOLIO

19.20.3 RECENT DEVELOPMENT

19.21 STRECK

19.21.1 COMPANY SNAPSHOT

19.21.2 PRODUCT PORTFOLIO

19.21.3 RECENT DEVELOPMENTS

19.22 SYSMEX INOSTICS INC.

19.22.1 COMPANY SNAPSHOT

19.22.2 REVENUE ANALYSIS

19.22.3 PRODUCT PORTFOLIO

19.22.4 RECENT DEVELOPMENTS

20 QUESTIONNAIRE

21 RELATED REPORTS

Liste des tableaux

TABLE 1 WAYS IN WHICH LIQUID BIOPSY HAS ADVANCED PRECISION MEDICINE

TABLE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 3 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 5 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 6 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 7 ASIA-PACIFIC ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 8 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 9 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 10 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 11 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 12 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 13 ASIA-PACIFIC CIRCULATING TUMOR CELLS (CTCS) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 ASIA-PACIFIC CIRCULATING CELL-FREE DNA (CFDNA) IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 ASIA-PACIFIC CELL-FREE RNA IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 16 ASIA-PACIFIC EXOSOMES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 ASIA-PACIFIC EXTRACELLULAR VESICLES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 18 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 20 ASIA-PACIFIC BLOOD SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 ASIA-PACIFIC URINE SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 22 ASIA-PACIFIC SALIVA & OTHER TISSUE FLUIDS SAMPLE-BASED IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 25 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 27 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 29 ASIA-PACIFIC HISTOLOGY/IMAGING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 31 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 33 ASIA-PACIFIC BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 34 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 37 ASIA-PACIFIC ROUTINE SCREENING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 ASIA-PACIFIC THERAPY SELECTION IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 39 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 41 ASIA-PACIFIC RECURRENCE MONITORING IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 ASIA-PACIFIC PATIENT WORK-UP IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 43 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 45 ASIA-PACIFIC MULTI-GENE-PARALLEL ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 ASIA-PACIFIC SINGLE GENE ANALYSIS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 48 ASIA-PACIFIC HOSPITALS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 ASIA-PACIFIC REFERENCE LABORATORIES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 50 ASIA-PACIFIC DIAGNOSTICS CENTERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 ASIA-PACIFIC RESEARCH CENTRES AND ACADEMIC INSTITUTES IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 52 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 54 ASIA-PACIFIC DIRECT TENDER IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 ASIA-PACIFIC THIRD PARTY DISTRIBUTOR IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 56 ASIA-PACIFIC OTHERS IN LIQUID BIOPSY MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 58 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 59 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 60 ASIA-PACIFIC CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 61 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 62 ASIA-PACIFIC TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 63 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 64 ASIA-PACIFIC COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 65 ASIA-PACIFIC ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 66 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 67 ASIA-PACIFIC INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 68 ASIA-PACIFIC SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 69 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 70 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 71 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 72 ASIA-PACIFIC MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 73 ASIA-PACIFIC PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 74 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 75 ASIA-PACIFIC CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 76 ASIA-PACIFIC BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 77 ASIA-PACIFIC NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 78 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 79 ASIA-PACIFIC TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 80 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 81 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 82 ASIA-PACIFIC LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 83 JAPAN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 84 JAPAN CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 85 JAPAN CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 86 JAPAN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 87 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 88 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 89 JAPAN TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 90 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 91 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 92 JAPAN COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 93 JAPAN ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 94 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 95 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 96 JAPAN INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 97 JAPAN SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 98 JAPAN LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 99 JAPAN LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 100 JAPAN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 101 JAPAN MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 102 JAPAN PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 103 JAPAN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 104 JAPAN CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 105 JAPAN BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 106 JAPAN NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 107 JAPAN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 108 JAPAN TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 109 JAPAN LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 110 JAPAN LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 111 CHINA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 112 CHINA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 113 CHINA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 114 CHINA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 115 CHINA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 116 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 117 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 118 CHINA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 119 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 120 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 121 CHINA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 122 CHINA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 123 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 124 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 125 CHINA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 126 CHINA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 127 CHINA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 128 CHINA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 129 CHINA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 130 CHINA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 131 CHINA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 132 CHINA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 133 CHINA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 134 CHINA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 135 CHINA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 136 CHINA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 137 CHINA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 138 CHINA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 139 CHINA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 140 CHINA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 141 SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 142 SOUTH KOREA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 143 SOUTH KOREA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 144 SOUTH KOREA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 145 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 146 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 147 SOUTH KOREA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 148 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 149 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 150 SOUTH KOREA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 151 SOUTH KOREA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 152 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 153 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 154 SOUTH KOREA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 155 SOUTH KOREA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 156 SOUTH KOREA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 157 SOUTH KOREA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 158 SOUTH KOREA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 159 SOUTH KOREA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 160 SOUTH KOREA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 161 SOUTH KOREA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 162 SOUTH KOREA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 163 SOUTH KOREA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 164 SOUTH KOREA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 165 SOUTH KOREA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 166 SOUTH KOREA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 167 SOUTH KOREA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 168 SOUTH KOREA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 169 SOUTH KOREA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 170 INDIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 171 INDIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 172 INDIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 173 INDIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 174 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 175 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 176 INDIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 177 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 178 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 179 INDIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 180 INDIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 181 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 182 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 183 INDIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 184 INDIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 185 INDIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 186 INDIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 187 INDIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 188 INDIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 189 INDIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 190 INDIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 191 INDIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 192 INDIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 193 INDIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 194 INDIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 195 INDIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 196 INDIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 197 INDIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 198 INDIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 199 AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 200 AUSTRALIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 201 AUSTRALIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 202 AUSTRALIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 203 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 204 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 205 AUSTRALIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 206 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 207 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 208 AUSTRALIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 209 AUSTRALIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 210 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 211 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 212 AUSTRALIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 213 AUSTRALIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 214 AUSTRALIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 215 AUSTRALIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 216 AUSTRALIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 217 AUSTRALIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 218 AUSTRALIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 219 AUSTRALIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 220 AUSTRALIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 221 AUSTRALIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 222 AUSTRALIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 223 AUSTRALIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 224 AUSTRALIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 225 AUSTRALIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 226 AUSTRALIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 227 AUSTRALIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 228 SINGAPORE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 229 SINGAPORE CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 230 SINGAPORE CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 231 SINGAPORE LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 232 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 233 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 234 SINGAPORE TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 235 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 236 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 237 SINGAPORE COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 238 SINGAPORE ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 239 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 240 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 241 SINGAPORE INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 242 SINGAPORE SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 243 SINGAPORE LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 244 SINGAPORE LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 245 SINGAPORE LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 246 SINGAPORE MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 247 SINGAPORE PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 248 SINGAPORE LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 249 SINGAPORE CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 250 SINGAPORE BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 251 SINGAPORE NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 252 SINGAPORE LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 253 SINGAPORE TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 254 SINGAPORE LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 255 SINGAPORE LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 256 SINGAPORE LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 257 THAILAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 258 THAILAND CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 259 THAILAND CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 260 THAILAND LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 261 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 262 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 263 THAILAND TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 264 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 265 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 266 THAILAND COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 267 THAILAND ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 268 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 269 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 270 THAILAND INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 271 THAILAND SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 272 THAILAND LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 273 THAILAND LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 274 THAILAND LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 275 THAILAND MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 276 THAILAND PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 277 THAILAND LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 278 THAILAND CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 279 THAILAND BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 280 THAILAND NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 281 THAILAND LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 282 THAILAND TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 283 THAILAND LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 284 THAILAND LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 285 THAILAND LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 286 MALAYSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 287 MALAYSIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 288 MALAYSIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 289 MALAYSIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 290 MALAYSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 291 MALAYSIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 292 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 293 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 294 MALAYSIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 295 MALAYSIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 296 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 297 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 298 MALAYSIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 299 MALAYSIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 300 MALAYSIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 301 MALAYSIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 302 MALAYSIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 303 MALAYSIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 304 MALAYSIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 305 MALAYSIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 306 MALAYSIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 307 MALAYSIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 308 MALAYSIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 309 MALAYSIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 310 MALAYSIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 311 MALAYSIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 312 MALAYSIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 313 MALAYSIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 314 INDONESIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 315 INDONESIA CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 316 INDONESIA CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 317 INDONESIA LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 318 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 319 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 320 INDONESIA TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 321 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 322 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 323 INDONESIA COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 324 INDONESIA ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 325 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 326 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 327 INDONESIA INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 328 INDONESIA SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 329 INDONESIA LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 330 INDONESIA LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 331 INDONESIA LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 332 INDONESIA MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 333 INDONESIA PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 334 INDONESIA LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 335 INDONESIA CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 336 INDONESIA BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 337 INDONESIA NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 338 INDONESIA LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 339 INDONESIA TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 340 INDONESIA LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 341 INDONESIA LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 342 INDONESIA LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 343 PHILIPPINES LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 344 PHILIPPINES CONSUMABLES & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 345 PHILIPPINES CONSUMABLE & ACCESSORIES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 346 PHILIPPINES LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 347 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 348 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 349 PHILIPPINES TEST KITS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 350 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 351 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 352 PHILIPPINES COLLECTION TUBES IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (ASP)

TABLE 353 PHILIPPINES ASSAYS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 354 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 355 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (UNITS)

TABLE 356 PHILIPPINES INSTRUMENTS IN LIQUID BIOPSY MARKET, BY PRODUCTS, 2021-2030 (ASP)

TABLE 357 PHILIPPINES SERVICES & SOFTWARE IN LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

TABLE 358 PHILIPPINES LIQUID BIOPSY MARKET, BY BIOMAKER TYPE, 2021-2030 (USD MILLION)

TABLE 359 PHILIPPINES LIQUID BIOPSY MARKET, BY SAMPLE TYPE, 2021-2030 (USD MILLION)

TABLE 360 PHILIPPINES LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 361 PHILIPPINES MOLECULAR IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 362 PHILIPPINES PROTEOMIC IN LIQUID BIOPSY MARKET, BY ANALYTICAL TYPE, 2021-2030 (USD MILLION)

TABLE 363 PHILIPPINES LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 364 PHILIPPINES CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 365 PHILIPPINES BREAST IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 366 PHILIPPINES NON-CANCER APPLICATIONS IN LIQUID BIOPSY MARKET, BY APPLICATION TYPE, 2021-2030 (USD MILLION)

TABLE 367 PHILIPPINES LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 368 PHILIPPINES TREATMENT MONITORING IN LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, 2021-2030 (USD MILLION)

TABLE 369 PHILIPPINES LIQUID BIOPSY MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)

TABLE 370 PHILIPPINES LIQUID BIOPSY MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 371 PHILIPPINES LIQUID BIOPSY MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 372 REST OF ASIA-PACIFIC LIQUID BIOPSY MARKET, BY PRODUCT, 2021-2030 (USD MILLION)

Liste des figures

FIGURE 1 ASIA-PACIFIC LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 2 ASIA-PACIFIC LIQUID BIOPSY MARKET: DATA TRIANGULATION

FIGURE 3 ASIA-PACIFIC LIQUID BIOPSY MARKET: DROC ANALYSIS

FIGURE 4 ASIA-PACIFIC LIQUID BIOPSY MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA-PACIFIC LIQUID BIOPSY MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA-PACIFIC LIQUID BIOPSY MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA-PACIFIC LIQUID BIOPSY MARKET: DBMR MARKET POSITION GRID

FIGURE 8 ASIA-PACIFIC LIQUID BIOPSY MARKET: MARKET TESTING TYPE COVERAGE GRID

FIGURE 9 ASIA-PACIFIC LIQUID BIOPSY MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA-PACIFIC LIQUID BIOPSY MARKET: SEGMENTATION

FIGURE 11 THE GROWING DEMAND FOR NON-INVASIVE CANCER DIAGNOSTICS IS EXPECTED TO DRIVE THE ASIA-PACIFIC LIQUID BIOPSY MARKET GROWTH IN THE FORECAST PERIOD

FIGURE 12 CONSUMABLES & ACCESSORIES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA-PACIFIC LIQUID BIOPSY MARKET

FIGURE 14 ADVANTAGES OF LIQUID BIOPSY OVER TRADITIONAL BIOPSY

FIGURE 15 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, 2022

FIGURE 16 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, 2023-2030 (USD MILLION)

FIGURE 17 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, CAGR (2023-2030)

FIGURE 18 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 19 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2022

FIGURE 20 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, 2023-2030 (USD MILLION)

FIGURE 21 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, CAGR (2023-2030)

FIGURE 22 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY BIOMAKER TYPE, LIFELINE CURVE

FIGURE 23 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2022

FIGURE 24 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, 2023-2030 (USD MILLION)

FIGURE 25 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, CAGR (2023-2030)

FIGURE 26 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 27 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2022

FIGURE 28 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, 2023-2030 (USD MILLION)

FIGURE 29 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, CAGR (2023-2030)

FIGURE 30 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY ANALYTICAL TYPE, LIFELINE CURVE

FIGURE 31 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2022

FIGURE 32 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, 2023-2030 (USD MILLION)

FIGURE 33 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, CAGR (2023-2030)

FIGURE 34 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY APPLICATION TYPE, LIFELINE CURVE

FIGURE 35 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2022

FIGURE 36 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)

FIGURE 37 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, CAGR (2023-2030)

FIGURE 38 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY CLINICAL APPLICATION, LIFELINE CURVE

FIGURE 39 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2022

FIGURE 40 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)

FIGURE 41 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, CAGR (2023-2030)

FIGURE 42 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY TECHNOLOGY, LIFELINE CURVE

FIGURE 43 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, 2022

FIGURE 44 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 45 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, CAGR (2023-2030)

FIGURE 46 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY END USER, LIFELINE CURVE

FIGURE 47 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 48 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 49 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 50 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 51 ASIA-PACIFIC LIQUID BIOPSY MARKET: SNAPSHOT (2022)

FIGURE 52 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2022)

FIGURE 53 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2023 & 2030)

FIGURE 54 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY COUNTRY (2022 & 2030)

FIGURE 55 ASIA-PACIFIC LIQUID BIOPSY MARKET: BY PRODUCT (2023-2030)

FIGURE 56 ASIA-PACIFIC LIQUID BIOPSY MARKET: COMPANY SHARE 2022 (%)

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.

Questions fréquemment posées

Japan is expected to dominate the Asia-Pacific liquid biopsy market due to technological advancements in liquid biopsy platforms in the country.
The growth rate of the Asia-Pacific liquid biopsy market is 13.4%.
Growing demand for non-invasive liquid biopsy technique & Advancements in precision medicine due to liquid biopsy are the growth drivers of the Asia-Pacific liquid biopsy market.
Product, Biomaker type, sample type, analytical type, application type, clinical application, technology, end user, and distribution channel are the factors on which the Asia-Pacific liquid biopsy market research is based.
Major companies in the Asia-Pacific liquid biopsy market are F. Hoffmann-La Roche Ltd, Guardant Health, Thermo Fisher Scientific Inc., Exact Sciences Corporation (Genomic health), QIAGEN, Labcorp, Johnson & Johnson Services, Inc., Illumina Inc, NeoGenomics Laboratories, Bio-Rad Laboratories, Inc., Natera, Inc., CARDIFF ONCOLOGY, INC., Sysmex Inostics Inc., and BIOCEPT, INC. among others.